the right. She also noted that intermittent aural fullness had been present for the previous 2 months . Like the tinnitus, it occurred in both ears, but more often in the right. However, the fullness and the tinnitus were not correlated.
A clinical neurotologic examination yielded a few positive findings, including diplacusis with the 2-kHz tuning fork and difficulty performing the sharpened tandem Romberg's test. The patient produced previously performed tests. Although audiometry revealed that the patient's hearing was normal , close examination of the acoustic immittance results showed a borderline shallow tympanometry in both ears and a negative deflection of the ipsilateral acoustic stapedial reflexes on the right. ]:!:ttl! j:rl:
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A 48-year-old woman came to the office with an 8-month history of dizziness . The dizziness had begun as a brief rotary vertigo that lasted a few minutes and that was accompanied by numbness on the left side of her face. In time, the patient also had begun to experience light-headedness and numbness in her lower body. She had undergone an evaluation for her condition, which had included a lumbar puncture . Following the puncture, she experienced a 7day period of rotary vertigo. Afterward, she continued to experience dizziness when changing positions and while in motion. She eventually became confined to bed for 2 weeks , and she later underwent nutritional therapy, chiropractic therapy, and vestibular rehabilitation. But then her symptoms abated to a point where she would experience entire days free of symptoms. However, on days when she woke up with a feeling of unnatural motion, she would be dizzy all day. She felt worst when she was in shopping malls and when she was fatigued . Her dizziness also became exacerbated when she turned to the left while standing and when she turned over in bed.
At the author's office, the patient denied subjective hearing loss. She said that tinnitus had been present around the time of the lumbar puncture. She characterized her tinnitus as a high-pitched humming sound that was present intermittently in either ear, but more frequently in From Neurotologic Associates, P.C., New York City.
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For the relief of symptoms of seasonal allergic rhinitis in adults and children as young as 2 years
In clinical trials , SINGULAIR was generally well tolerated , with a safety profile similar to that of placebo. Adverse events varied by age. The most commonly reported adverse events, regardless of causality assessment, were headache , otitis media, pharyngitis, and upper respiratory infection. SINGULAIR is contra indicated in patients with hypersensitivity to any component of this product. 
NEW FOR SEASONAL ALLERGIC RHINITIS

S'NGUI.AlR
(MONTELUKAST SODIUM)
A Decisively Different Way to Allergy Relief Brief Summary ofPrescribing Information: SINGULAIR" (montelukast sodium) tablets and chewable tablets INDICATIONS AND USAGE SINGULAIR is indi cated for the prophylaxis and chronic treatment of asthma in adults and pedi atri c patients 2 years of age andolder. SING ULAIR is indicated for the rel ief of symptoms of seasonal allergic rhinitis in adults and pediatric pati ents 2 years of age and older.
CONTRAINDICATIONS
Hypersensitivity to any component of this product.
PRECAUTIONS
General : SINGULAIR is not indicated for use in the reversal of bronchospasm in acuteasthmaattacks, including statusasthmaticus. Patients should be advised to haveappropriate rescue medicationavailable. Therapy wit h SINGULAIR can be continued during acute exacerbations ofasthma. Whilethedose of inhaled cort icosteroi dmaybereduced graduallyunder medical supervision, SINGULAIRshould notbe abr uptlysubstituted forinhaled or oral corticosteroids. SINGULAIR should not be used as monother apy for the treatment and management ot exer cise-induced bronchospasm. Pat ient s who have exacerbationsof asthmaafte r exercise should cont inue to use their usual regimen ofinhal ed~a go n i s ts asprophyl axis and have availableforrescueashort-acting inhal ed~ag oni s t . Patients wi th knownaspirin sensitivityshould continue avoidance of aspirin or non-steroi dalanti-inflammatory agentswhiletaking SINGULAIR.AlthoughSINGULAIRiseffective inimprovingairway functioninasthmaticswi th documented aspi rinsensitivity, it has not been shown to truncate bronchoconstri ctorresponse to aspirinand other non-steroidal anti-inflammatory drugs in aspirin-sensitive asthmatic patients (see CLINICAL PHARMACOLOGY, Clinical Studies, inthe Prescribing Informati on). Eosinophilic Conditions: In rare cases, pati ents with asthma on therapy wi th SINGULAIR may present with systemic eosinophilia, sometimes presenting with clinical features of vasculitis consistent with Churg-St rauss syndrome, acondi tion which is oftentreatedwi thsystemiccorticosteroid therapy. Theseeventsusually, but not always, havebeenassociated with the reducti on of oral corticosteroid ther apy. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal association between SI NGULAIRand these underl ying conditions has not beenestablished (see ADVERSEREACTIONS).
Information forPatients
• Pati entsshouldbeadvisedtotakeSINGULAIRdailyasprescribed, evenwhenthey areasymptomatic,as well asduring peri odsof worseningasthma, andtocont acttheirphysici ans if their asthmais not well controlled. • Patients should be advised that oral SINGULAIR is not for the treatment of acute asthma attacks. They should haveappropriateshort-acting inhal ed~a g oni st medicati onavailableto treatasthmaexacerbations. • Pati ents should beadvised that, whileusi ngSINGULAIR, medical attentionshould besought if short -acting inhal ed bronchodilators are needed more often than usual , or if more than the maximum number of inhal ations of short-acting bronchodil ator treatment prescribedfora24-hourperiodareneeded. • Patients recei vingSINGULAIR should beinstructednot to decrease thedose or stoptaking anyother anti-asthmamedicati ons unl ess instructed by a physician. • Patients whohaveexacerbat ionsof asthmaafterexercise should beinstructedto continue to usetheir usual regimenofinhal edp-aaonists asprophylaxis unless otherwise instructedby theirphysician. All patient s should haveavailable for rescuea short-actinginhal ed~ag on i st. • Patients wi th knownaspi rin sensitivityshould be advisedto continue avoidance of aspirin or non-steroidal anti-inflammatoryagentswhiletaking SINGULAIR. Chewable Tablet s • Phenylketonurics:Phenylketonuric pati ents shouldbeinformedthat the4-mg and 5-mgchewable tablets contain phenylal anine (acomponent of aspartame), 0.674 and 0.842 mgper4-mg and 5-mg chewable tabl et,respecti vel y. Drug Interactions: SINGULAIR has been administered with other therapies routinely used in the prophylaxis and chronic treatment of ast hma with no apparent increase in adverse reactions. In drug-interactionstudies, the recommendedclinical dose of montel ukast did not have clinically important effects on the pharmacokineti cs of the foll owing drugs: theophylline, prednisone, predni solone, oral cont raceptives (norethindrone 1 mg/ethinyl estradiol 35meg), terfenadine, digoxin, and warfarin. Althoughadditional specific interaction studieswerenot performed, SINGULAIRwas usedconcomitantly with a widerangeof commonly prescribed drugs in clinical studies without evidence of clinical adverse interactions.These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatoryagents, benzodi azepines, anddecongestants. Phenobarbital , which induces hepatic metabolism, decreasedtheAUC of rnont el ukast approximately 40% following a single 10-mg dose of mont elukast.No dosageadjustment for SINGULAIRis recommended. It is reasonableto employappropriate clinical monitoring when pot entcytochromeP450enzymeinducers, such asphenobarbitalor rifampin, areco-administered wi th SINGULAI R. Carcinogenesis, Mutagenesis, Impairment of Fert ility: Noevidence of tumorigeni city was seen in either a 2-year carcinogenicitystudyin Sprag ue-Dawleyratsat oralgavagedoses up to 200 mg/kg/day (estimated exposure was approxi mately90 times the area underthe plasmaconcentration versustime curve (AUC) for adults and childrenat the maximum recommendeddail y oral dose) or in a 92-week carcinogenicity studyin miceatoral gavagedoses upto 100 mg/kg/day (estimatedexposurewas approximately 30 times theAUC for adul ts and children at the maximum recommended daily oral dose). Mont elukast demonstratedno evidence of mut agenic or clastocenlcactivity in the following assays: the mi crobi al mutagenesis assay, the V-79 mammalian cell mutagenesis assay, the alkaline elution assayin rat hepatocytes, the chromosomal aberration assay in Chinese hamster ovary cells, and in the in vivo mouse bone marrow chromosomal aberration assay. Infertili ty studies infemalerats, rnontelukast produced reductions in fertilityandfecundity indi ces at anoral dose of 200 mglkg (estimated exposurewas approximately 70times the AUC for adults at the maximum recommended daily oral dose). No effects on femal efertility or fecundity wereobserved atan oral doseof 100 mg/kg (estimated exposure was approximately 20 times the AUC for adul ts at the maximum recommend ed daily oral dose). Mont elukast had no effects on fertility in mal e rats at oral doses up to 800 mg/kg (estimated exposure was approxi mately 160 times the AUC for adults at the maximum recommended daily oraldose). Pregnancy, Teratogenic Eff ects Pregnancy Category B: Noteratogenicity was observed in rats at oral doses upto 400 mg lkg/day (estimated exposurewasapproximately 100times theAUC for adults atthe maximum recommendeddail y oral dose) and in rabbi tsatoral doses upto 300 mg/kg/day (estimated exposurewas approximately110times theAU C for adul ts at the maximum recommend ed daily oral dose). Montelukast crosses the placentafoll owing oral dosing in rats andrabbits. Thereare, however, no adequateandwell-controlled studies in pregnantwomen. Because animal reproducti onstudiesare not always predi cti ve of human response, SINGULAIRshoul d be used during pregnancy only if clearly needed. Merck & Co., Inc. maintains a reg istry to monitor the pregnancy outcomes of women exposed to SINGULAIR while preg nant. Healthcare providers are encouraged to report any prenatal exposure to SINGULAIR by callingthe PregnancyRegistry at (800) 986-8999. Nursing Mothers: Studi es in rats have shown that montelukast is excreted in mil k. It is not known if montelukast is excreted in humanmil k. Because many drugs areexcreted in humanmilk, cautionshould be exercised when SINGULAIRis gi vento a nur sing mother.
PediatricUse: Safety andeff icacyof SING ULAIR' (montelukast sodium)have been established inadequateand well-controlled studies inpediatric patientswithasthma 6to14years ofage. Safety and efficacy profiles inthis age group are similartothoseseeninadults. (See Clinical Studies inthe Prescribing Informati onandADVERSE REACTIONS.) Theefficacy of SINGULAIRfor thetreatment of seasonal allergic rhinitis in pediatric patients 2 to 14years of age is supported byext rapolation fromthe demonstrated efficacy in pati ent s 15 years of age and older with seasonal allergic rhiniti s aswell astheassumpt ionthatthedisease course, pathophysiology andthe drug's effect are substant ially similaramongthese populations. Thesafety of SI NGULAIR4-mg chewable tablet s inpediat ric patients 2to 5yearsofage withasthma has been demonstrated byadequa teandwell-controlleddat a(see ADVERSEREACTIONS). Efficacy ofSI NGULAIRinthis age group is extrapolatedfrom thedemonstratedefficacy inpa tients6years of age andol der withast hmaand is based onsimilarpharmacoki netic data, aswell asthe assumption that thedisease course, pathophysiology and thedrug's effect aresubstantiallysimilar amongthesepopul ations. Efficacy inthis age group is supported byexploratoryefficacy assessmentsfromalarge,well-controlled safety studyconductedinpatients2to5years of age. The safety of SING ULAIR4-mg and 5-mgchewable tablets in ped iatric pati ents aged 2 to 14years with seasonal allergic rhinitis is supported by data from studies conductedin pedi atri c patients aged 2 to 14 years with ast hma. A safetystudyin pediatric patients 2 to 14 years of age with seasonal allergic rhinitis demonstrated a similar safety profile (see ADVERSEREACTIONS). Thesafety andeffectiveness inpedia tricpatientsbelowtheage of2yearshavenotbeenestablished. Long-term trial s evaluating theeffect of chronic administration of SiNGULAIR on lineargrowth in pediatric pa tients have notbeenconducted. GeriatricUse: Ofthetotal numberof SUbjects inclinica l studies ofmont elukast. 3.5% were 65yearsof age and over and 0.4% were 75years of age and over. No overall differences in safety or effectiveness were observed between these SUbjects and younger SUbjects, and other report ed clinical experience has not identified differences in responses between the elderly and younger pat ients, but greater sensi tivity of some older individualscannotberul ed out.
ADVERSE REACTIONS
Adults andAdolescents 15Years of Age andOlder wi thAsthma: SINGULAIRhas been evaluated for safety in approximately 2600 adul t and adolescent patients 15 years of age and older in clinical trial s. In pl acebo-controll ed clinical trial s, thefoll owing adverse experiences reported wi th SINGULAIRoccurred inzt % of pa tients and at an incidence great er than that in pati ents treated with placebo, regardless of causality assessment: SINGULAIR 10 mg/day (n=1955) vs pl acebo (n=1180), respecti vel y. Body as a whole: asthenia/ fatigue (1.8%vs 1.2%); fever (1.5% vs 0.9%); pain, abdominal (2.9% vs 2. 5%); trauma (1.0% vs 0.8%). Digestive syste mdisorders: dyspepsia (2.1% vs 1.1 %); gastroenteritis,inf ectious (1.5% vs 0.5%); pain, dental (1.7% vs 1.0%). Nervoussystem/psychiatric: dizziness (1.9% vs 1.4%); headache (18.4% vs 18.1 %). Respiratorysyste mdisorders:congestion, nasal(1.6%vs1.3%);cough(2.7%vs2.4%); influenza(4.2% vs3.9%). Skin/ skin appendages disorder: rash (1.6% vs 1.2%). Labor atory adverse experiences (number of pa tients tested [SINGULAIR andpl acebo, respectivel y]: ALT andAST, 1935, 11 70; pyur ia, 1924, 11 59) : ALT increased (2. 1% vs2.0%); ASTincreased (1.6%vs1.2%); pyuria (1.0%vs0. 9%). Thefrequency oflesscommon adverse eventswas comparable between SINGULAIRand placebo. Cumulat ively, 569 patients weretreated withSINGULAIRforat least6 months, 480foroneyear, and49 fortwo years inclinical trials.Withprol ongedtreatment, the adverse experience prof iledid not significantlychange. Pediatric Patients 6 to 14 Years of Age wit h Asthma: SINGULAIR has been evaluated for safety in 321 pediatric patients6 to 14years of age. Cumulatively, 169 pedi atric patient s weretreated with SINGULAIRfor at least 6 months, and 121 for one year or longer in cli nical trial s. The safetyprofile of SING ULAIR in the 8-week, double-blind, pediatric eff icacy trial was generally similar to the adult safetyprofi le. In pedi atri c patients 6 to 14yearsof age receiving SINGULAIR, thefoll owing events occurred with afrequency ;,2%and more frequently than in pediatric patients who recei ved pl acebo, regardless of causality assessment: pharyng itis, influenza, fever, sinusitis, nausea, diarrhea, dyspepsia, otitis, viral infection, and laryngitis. The frequ ency of less common adverse events was comparable bet ween SINGULAIR and place bo. With prolonged treatment, theadverse experience profiledi d not significantlychange. Pediatric Patients 2 to5 Years ofAge wi thAsthma: SI NGULAIRhas been evaluated for safety in573pedi atric patients2to5yearsofageinsingleand mul tipl edose studies. Cumulati vely, 426pediatricpatients 2to 5years weretreated with SINGULAIRfor at least 3 months, 230 for6 months or longer, and 63pati ents foroneyear or longer inclinical trials. SINGULAIR4 mgadmi nistered once dailyatbedtimewas generally well tol eratedin clinical trials. Inpediatric patients 2 to 5 yearsof age recei ving SINGULAIR,thefoll owing events occurredwith a frequency ;,2%andmorefrequently thanin pediatric patients whorecei vedpl acebo, regardless of causality assessment:fever,cou gh,abdominal pain, diarrhea,headache, rhinorrhea, sinusi tis, otitis, influenza, rash, ear pain, gastroenteri tis, eczema, urti caria, var icella, pneumonia, dermatitis,andconjunctivitis. Adults andAdolescents 15 Years of Age andOlder with Seasonal Allergic Rhinitis: SING ULAIR has been evaluated for safety in 2199adul t and adolescent patients 15 years of age and older in clinical trial s. SINGULAIR administered once daily in the morning or in the evening wasgenerally well tolerated with a safety profilesimi lar to that of pl acebo. In pl acebo-controlled clini caltrials, thefoll owing eventwas reported wi th SING ULAIRwith afrequencyof;,1%and at an incidence greater than pl acebo, regardless of causality assessment: upper respi ratory infection, 1.9% of patients receiving SINGULAIR vs. 1.5% of patient s recei vingplacebo. Ina 4-week, pl acebo-controll ed clinical study , the safetyprofil ewas consistent with fhat observed in 2-week studies. The incidence of somnolence was similar to that of pl acebo inall studies. Pediatric Patients 2 to 14Years of Age with Se asonal Allergic Rhinitis: SINGULAIRhas been evaluated in280 pedi atri c patients 2 to 14 years of age in a 2-week, mul ticent er, double-blind, pl acebo-cont roll ed, parall el -group, safety study. SINGULAIRadministered once daily in theeveni ngwas generallywell tol erated with a safety prof ile similarto that of pl acebo. Inthis study, the foll owing events occurred with afrequency ;,2% and at an incidence greater than pl acebo, regardless of causality assessment: headache, oti tis medi a, pharyngitis,and upperrespiratory infection. Post-Marketing Experience: The following additional adve rse reactions have been reported in post-marketinguse: hypersensitivity reactions (including anaphylaxis, angioedema, pruritus, urticari a, and very rarel y, hepatic eosinophilic infiltration); dream abnormali ties and hallucinati ons, drowsiness, irritability, agi tation including aggress ive behavior, restlessness, insomnia, and very rarel y seizures; nausea, vomiting, dyspepsi a, diarrhea, and very rareiy pancreatitis; arthralgia, myalgia inclUding muscle cramps; increased bl eeding tendency, bruising ; palpitations; and edema. In rare cases, patients with asthmaon therapy with SINGULAIR may present wi th systemic eosinophi lia, sometimes presentingwithclinical featuresofvasculi tisconsistent withChurg-Strauss syndrome, acondi tion which is often treated with systemic corticosteroid therapy. These events usuall y, butnot always, have been associ ated with the reduction of oral corticosteroid therapy. Physi cians should be alert to eosinophilia, vasculitic ras h,worsening pulmonarysymptoms, card iac complications, and/or neur opathy presenti ngintheir pati ent s. A ca usal association bet weenSING ULAIRand these underl yingconditionshas notbeen established (see PRECAUTI ONS, Eosinophilic Conditions Electronystagmography showed a markedly reduced response to warm stimulus in the right ear, which led to a 37% directional preponderance. Sinusoidal vertical-axis rotation testing elicited normal gains and phases but abnormal symmetry to the right at two frequencies.
Six months later, the patient underwent follow-up testing. While her hearing was still in the normal range , it had declined slightly since her previous examination, more so in the right ear. One finding on tympanometry was a nearshallow or stiff curve on the right. Acoustic stapedial reflexes were absent in both ears at 0.5 kHz. The simultaneous binaural bithermal test elicited a type 1 response.
On metabolic evaluation, the patient's glucose tolerance test results were flat and her serum insulin levels were elevated. Findings on ultrathin computed tomography of the temporal bones were consistent with otosclerosis of the labyrinthine capsule, which was more pronounced on the right. She was placed on a diet to address her metabolic factors and prescribed the bisphosphonate etidronate and calcium to address her otosclerosis.
When the patient returned 3 months later, she reported improvement. Although her dizziness was still present intermittently, its severity and duration were much less pronounced. She reported less tinnitus and less aural fullness . Her regimen was continued.
When the patient returned in 4 months, she reported continued imp rovement. Her spontaneous spells of dizziness were less common, and periods when she felt no dizziness were more frequent and longer lasting . Her tinnitus and aural fullness were much less pronounced, and the numbness in her face had disappeared. She was switched to a different bisphosphonate (risedronate), and sodium fluoride was added to her regimen. The patient returned 3 months later and reported that her dizziness was 95 % resolved. Her tinnitus occurred very seldomly, and her aural fullness had disappeared. Seven months later, the dizziness was completely gone.
A number of findings in this case should be highlighted. One significant finding was the directional preponderance ofthe alternate binaural bithermal caloric stimulus in a patient with her history. The second important finding was the abnormal symmetry on sinusoidal vertical-axis rotation testing, which provided additional objective findings consistent with her symptoms. Third, the simultaneous binaural bithermal test played no significant diagnostic role in this case, which is unusual. Fourth, a flat glucose tolerance test result is considered by most endocrinologists to be a variant of normal, but in this patient, the glucose level played a significant role in her symptoms . Finally, the acoustic immittance findings , warmwater caloric response, and clinical symptoms were all consistent with the imaging findings. 
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